drugset / Trial / NCT04501653

Precision Functional Brain Mapping in Psilocybin

NCT04501653

Phase 0 Completed 11 enrolled Washington University School of Medicine
RandomizedCrossoverSingle-blindBasic science

Summary

This project will employ functional brain imaging to study the mechanism and immediate and long-term effects of psilocybin, a serotonin receptor 2A agonist, on cortical and cortico-subcortical brain networks in healthy adults.

Timeline

Start
2021-06-01
Primary completion
2023-03-19
Completion
2023-03-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylphenidate Small molecule 40 mg Oral
Subject Psilocybin Other / unclassified 25 mg Oral

Indications

No indication recorded.